Samaritan: Caprospinol for Alzheimer's shows favorable results in acute toxicity study

By Lisa Kerner

Charlotte, N.C., Aug. 29 - Samaritan Pharmaceuticals, Inc. said its Alzheimer's research compound Caprospinol (SP-233) demonstrated no toxicity when administered orally in an acute toxicity study.

Caprospinol demonstrated neuroprotective properties in preclinical studies against beta-amyloid-induced toxicity, possibly indicative of a treatment for Alzheimer's disease, according to a company news release.

In the latest study, Caprospinol was given at doses of 1, 3, 10, or 30 mg/kg/day, once daily, for three consecutive days, in male and female mice, and showed no acute toxicity at the concentrations tested. Samaritan said the no-observed-effect level was 30 mg/kg, for both male and female mice.

The company said it is very close to filing an Investigational New Drug application for Caprospinol with the Food and Drug Administration.

Las Vegas-based Samaritan develops and commercializes innovative therapeutics' for AIDS, Alzheimer's disease, cancer and heart disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.